HRTSTema Heart & Health ETF

Grow my money2y track recordRanked #2,259 of 2,960 in this goal

Seeks to provide long-term growth of capital.

By Tema Global Limited · Launched 2023

Annual Cost

0.75%

#3,765 of 5,562 · expensive

Fund Size

$52M

#3,545 of 5,562 · mid-size

Return (1Y)Goal

+22.2%

Track Record

2 years

#3,299 of 5,562 · seasoned

Performance

Total-return NAV · USD

Growth of $10,000

$12,165+21.7%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Active selection

Focus

Obesity & GLP-1

What it actually holds

By weight

Concentration

Top 10 holdings = 43.9% of fundmoderately concentrated

Eli Lilly & Co

10.6%

Roche Holding AG

4.4%

AstraZeneca PLC

4.3%

UnitedHealth Group Inc

4.1%

Abbott Laboratories

3.8%

Gilead Sciences Inc

3.7%

Thermo Fisher Scientific Inc

3.6%

Boston Scientific Corp

3.3%

Johnson & Johnson

3.1%

Medtronic PLC

3.1%

Asset allocation

Stocks

99.3%

Cash

0.7%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

16.2%Moderate

Year-on-year price swings

Max drawdown

-25.8%Moderate

Worst peak-to-trough loss

Sharpe (3Y)

Unavailable

Needs 3+ years of history

Sortino (3Y)

Not yet

Needs 3+ years of history

Where to buy

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks to provide long-term growth of capital.
Strategy: Invests primarily in companies deriving revenue from GLP-1 and cardiovascular/metabolic disease treatments. Focuses on growth companies in the U.S. and Europe, using both top-down and bottom-up analysis for security selection.
Inception date: November 20, 2023
Fund family: Tema Global Limited